Skip to main content
SpringerLink
Log in

Clinical Implications of the Survival with Oral D-Sotalol (SWORD) Trial: An Investigation of Patients with Left Ventricular Dysfunction after Myocardial Infarction

  • Published:
Cardiac Electrophysiology Review

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pitt B, Pratt CM, Rodda BE, Schwartz PJ, for the SWORD investigators. The SWORD trial. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design and methods. Am J Cardiol 1995;75:1023-1027.

    Google Scholar 

  2. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after myocardial infarction. Lancet 1996;348:7-12.

    Google Scholar 

  3. MacNeil DJ, Davies RO, Deitchman D. Clinical safety of sotalol in the treatment of arrhythmias. Am J Cardiol 1993; 72:44A-50A.

    Google Scholar 

  4. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.

    Google Scholar 

  5. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.

    Google Scholar 

  6. Echt DS, Leibson PR, Mitchell B, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, and the CAST investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324: 781-788.

    Google Scholar 

  7. Pratt CM. Introduction: the aftermath of the CAST-a reconsideration of traditional concepts. Am J Cardiol 1990; 65:1B-2B.

    Google Scholar 

  8. Pratt CM, Moyé LA. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. Am J Cardiol 1990;65:20B-29B.

    Google Scholar 

  9. Beta-Blocker Heart Attack Study Group. The Beta-Blocker Heart Attack Trial. JAMA 246:1981\(W\)73-2074.

    Google Scholar 

  10. Julian DG, Jackson FS, Prescott RJ, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;i:1142-1147.

    Google Scholar 

  11. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. An exploration of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials. Circulation 1996;93:519-524.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX

    Craig M. Pratt

Authors
  1. Craig M. Pratt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pratt, C.M. Clinical Implications of the Survival with Oral D-Sotalol (SWORD) Trial: An Investigation of Patients with Left Ventricular Dysfunction after Myocardial Infarction. Card Electrophysiol Rev 2, 28–29 (1998). https://doi.org/10.1023/A:1009982121597

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009982121597

Keywords

Search

Navigation